Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Bristol Myers Squibb CofiledCriticalUniv Rockefeller
Publication of AR105171A1publicationCriticalpatent/AR105171A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Anticuerpos agonistas, o porciones de fijación al antígeno de estos, que se fijan a CD40 humana. Dichos anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para FcgRIIb. También métodos para el tratamiento del cáncer o la infección crónica mediante la administración de los anticuerpos de la presente a un sujeto que lo necesita.Agonist antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with improved specificity for FcgRIIb. Also methods for the treatment of cancer or chronic infection by administering the present antibodies to a subject in need.
ARP160101948A2015-06-292016-06-28
ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY
AR105171A1
(en)